Retatrutide (formerly M25) is a next-generation multiagonist peptide targeting GLP-1, GIP, and glucagon receptors. Designed to address metabolic dysfunction at multiple regulatory nodes, it modulates appetite, glycemic control, and energy expenditure—positioning it as a promising candidate for significant weight reduction, improved insulin sensitivity, and comprehensive metabolic restoration.